Navigation Links
BD Rx Announces FDA Approval of High-Demand Injectable for Pain Management
Date:11/4/2013

significantly decrease pulmonary ventilation.  Morphine administration should be limited to use by those familiar with the management of respiratory depression. Rapid intravenous administration may result in chest wall rigidity.

Patients with chronic obstructive pulmonary disease or cor pulmonale and in patients having a substantially decreased respiratory reserve (e.g., severe kyphoscoliosis), hypoxia, hypercapnia or pre-existing respiratory depression have an increased risk of increased airway resistance and decrease respiratory drive to the point of apnea with use of Morphine Sulfate Injection USP.  Therefore, consider alternative non-opioid analgesics, and use Morphine Sulfate Injection USP only under careful medical supervision at the lowest effective dose in such patients.

Central Nervous System (CNS) Toxicity
Excitation of the central nervous system, resulting in convulsion, may accompany high doses of morphine given intravenously. Dysphoric reactions may occur after any size dose and toxic psychoses have been reported.

Central Nervous System (CNS) Depressants
The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistamines or psychotropic drugs. Use of morphine in conjunction with other CNS active drugs may increase the risk of respiratory depression, hypotension, profound sedation, coma, or death.

Increased Intracranial Pressure or Head Injury
Use Morphine Sulfate Injection with extreme caution in patients with head injury or increased intracranial pressure. In the presence of head injury, intracranial lesions or a preexisting increase in intracranial pressure, the possible respiratory depressant effects of Morphine Sulfate Injection USP and its potential to elevate cerebrospinal fluid pressure (resulting from vasodilation following CO2 retention) may be markedly exaggerated. Pupillary changes (miosis) from morphine may obscure the exi
'/>"/>

SOURCE BD (Becton, Dickinson and Company)
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. WuXi PharmaTech Announces Licensing Agreement for Patient-Derived Xenograft Models with Mayo Clinics Center for Individualized Medicine
2. VG Life Sciences, Inc. Announces the Initiation of IND-Enabling Animal Safety Studies
3. ISPE Announces Plans for Its Drug Shortages Initiative through 2014
4. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
5. IGI Laboratories, Inc. Announces Thirteenth ANDA Submission
6. Pharmagen Announces Shift In Growth Strategy
7. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2014 And Announces ARRY-520 Development Strategy
8. MSA Announces Fourth Quarter Dividend
9. Sorrento Therapeutics Announces Closing of Public Offering of Common Stock
10. Veracyte, Inc. Announces Pricing of Initial Public Offering
11. iHealth Announces Availability of Wireless Smart-Gluco Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... 2014 financial results after the Nasdaq market closes on ... live conference call and webcast to discuss its financial ... 7, 2014 at 8:00 a.m. Eastern Time (5:00 a.m. ... conference call by dialing 866-952-1907 (US) or 785-424-1826 (International) ...
(Date:7/29/2014)... Research and Markets has announced the addition ... report to their offering. ... medical device used to provide medication or assist a ... achieve adequate oxygen levels to maintain life. Patients with ... ARDS require the need of respiratory devices. The medication ...
(Date:7/29/2014)... 2014 Cynosure, Inc. (Nasdaq: ... light-based aesthetic treatment systems for high-volume applications, today reported ... 2014. Second-quarter 2014 financial results incorporate the acquisition of ... 2013. Second-Quarter 2014 Financial Highlights ... $72.6 million , Non-GAAP net income of $7.1 ...
Breaking Medicine Technology:Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2Global Respiratory Devices Market 2014-2018 2Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12
... Attached is a press release issued yesterday by GlaxoSmithKline (GSK), ... the American Diabetes Association 69th Scientific Sessions in New Orleans. ... ) , , Syncria is a biological product ... human GLP-1 peptide, and is designed to act throughout the ...
... , Oral Presentation Details Dose Optimization of Pre-Clinical ... 8 Tolerx, Inc., a biopharmaceutical company engaged ... for immune-mediated diseases, today presented results from a ... its Phase 3 anti-CD3 monoclonal antibody, otelixizumab, at ...
Cached Medicine Technology:FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight 2FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight 3Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 2Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association 3
(Date:7/30/2014)... According to the Yeast Infection No More book review ... will help candida sufferers get rid of their yeast ... to readers the truth about yeast infection and the real ... will discover natural and safe remedies to relieve symptoms of ... irritation of the vagina or vulva. , Vkool reveals ...
(Date:7/30/2014)... July 30, 2014 My Clients ... over 80 different electronic therapy note templates. Healthcare ... and other computing devices all while meeting the ... or electronic medial records (EMR) consist of psychological ... other essential categories. SOAP and DAP note ...
(Date:7/30/2014)... July 30, 2014 Regents Health Resources, ... services, has brought health care industry veteran Daryl Demonbreun ... to help lead the company’s ambitious plans to grow ... Health has been moving along at a steady pace ... it up a notch,” says Bob Maier, founder and ...
(Date:7/29/2014)... July 30, 2014 Recently, iFitDress.com, a well-known ... of satin bridal gowns . Aside from this, it ... prices, up to 68 percent off. All of its old ... , The company’s sales representative says excitedly, “We are pleased ... the new range, there are a lot of amazing items. ...
(Date:7/29/2014)... Dignity Sciences Limited, a privately held biopharmaceutical company, ... trial with DS107G, an oral formulation of Dihomo Gamma ... placebo-controlled, double-blind, single-ascending and multiple dose Phase I clinical ... food on DS107G in healthy subjects. , The ... both single and multiple oral doses over 28 days, ...
Breaking Medicine News(10 mins):Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 2Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 3Health News:My Clients Plus Announces Over 80 Online Therapy Notes to Help Healthcare Providers Go Paperless 2Health News:Sferrella and Demonbreun Join Regents Health Resources 2Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2
... Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced ... Annual Healthcare Conference will be webcast,live and may ... the Company,s,website, http://www.millennium.com ., (Logo: ... an update on VELCADE(R) (bortezomib) for,Injection and product ...
... Precyse to a leadership role, in Health Information ... Costs ... Precyse Solutions, the leader in,driving peak performance within Health ... as Senior Vice,President and Chief Information Officer. Joining Precyse in ...
... Acute Pain Prescription Drug ... ... Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) today announced that it has begun ... product (study 06CCL3-001)., "Tramadol-acetaminophen combination products have become widely,prescribed based ...
... 8 a.m. EDT, SHENZHEN, China, March 10 /Xinhua-PRNewswire-FirstCall/ ... ("Nepstar" or "the Company"), the,largest drugstore chain in China ... that it will report financial results for the,fourth quarter ... market,opens on March 19, 2008., The Company will ...
... March 10 Tea-based ingredients are now ... Colorado-based Sage,Group(R), a self-described ,tea think-tank, notes ... outnumber beverage,tea offerings on a global basis. ... other tea derivatives are being formulated into,thousands ...
... March 10 On March 23, the Easter,Bunny will ... goodies.,But, if you,re one of the lucky recipients, make ... your pets. Chocolate is poisonous to,dogs and cats, and ... equally as dangerous., Dr. Gregory S. Hammer, president ...
Cached Medicine News:Health News:Cowen & Company 28th Annual Healthcare Conference to Webcast Millennium Presentation 2Health News:Precyse Solutions Promotes Ken Lacy to Senior Vice President & CIO to Drive Advancement of PrecyseNet(TM), Precyse's Advanced Technology Solution 2Health News:Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen 2Health News:Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen 3Health News:China Nepstar Chain Drugstore to Announce Fourth Quarter 2007 Financial Results on March 19 2Health News:China Nepstar Chain Drugstore to Announce Fourth Quarter 2007 Financial Results on March 19 3Health News:Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products 2Health News:Tea Ingredients Publication Serves Robust Global Demand for Tea-Based Products 3Health News:AVMA: Keep Pets Safe This Easter 2
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
25L...
This fixed-volume digital micropipet is used to accurately measure and transfer 50 microliters of solution....
50L...
Medicine Products: